Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs MedLeanRx

By GLP-1 ScorecardUpdated

Kin Meds
Site position #148

Lower grade

MedLeanRx
Site position #74

Higher grade

Score comparison

MedLeanRx has the higher recorded score — 73.9/100 to 69.1/100.

MedLeanRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MedLeanRx is a physician-guided telehealth weight-loss clinic serving Texas only, based in Spring, TX.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueEven
74
74
Dose & formulationEven
93
93
Clinical oversightMedLeanRx +22
55
77
Labs & monitoringKin Meds +1
53
52
FulfillmentMedLeanRx +5
72
77
Contract termsEven
55
55
Kin Meds · top barMedLeanRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricKin MedsMedLeanRx
WeighScore69.1/10073.9/100
GradeCC
Site position#148#74
Semaglutide$149/mo (brand Wegovy)$149/mo (starting dose, promotional rate, compounded)
Tirzepatide$149/mo (brand Zepbound)$269/mo (starting dose, compounded)
CoverageCoverage not published1 state
Brand-name accessYesYes
Oral / sublingualYesYes
Kin Meds

Site position #148 · C

FDAWarning letter issued to Kin Meds in February 2026. See the FDA warning-letter database.

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

What to consider

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • FDA issued Kin Meds a warning letter in February 2026; the letter is public in FDA's warning-letter database
MedLeanRx

Site position #74 · C

Strengths

  • Compounded semaglutide $149/mo in both weekly injection and daily oral tablet form
  • Brand pathway for Wegovy, Zepbound, and Foundayo (orforglipron) at a $99/mo fee plus medication cost
  • Intro bundle: 2 months of compounded tirzepatide (2 mg weekly) for $325 — about $163/mo
  • LegitScript seal displayed; named supervising physician (Dr. Johnson Uzor, MD)
  • Free shipping, no hidden fees, and cancel-anytime plans per homepage trust chips

What to consider

  • Texas only — not available in the other 49 states
  • Compounded tirzepatide is $269/mo at standard pricing, above the ~$249 market median
  • Strict no-refund policy: 'All sales are final' per Terms & Conditions
  • Pharmacy partner not publicly named — a transparency gap for a compounding service
  • Legal entity name and founding details not published on the site

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard